CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017

(These consolidated financial statements are unaudited.)

Table of Contents

Consolidated Balance Sheets - September 30, 2017 (unaudited) and December 31, 2016	.2
Consolidated Statements of Comprehensive Income – Three-month and nine-month periods ended September 30, 2017 and 2016 (unaudited)	.3
Consolidated Statements of Shareholders' Equity – Nine-month periods ended September 30, 2017 and 2016 (unaudited)	.4
Consolidated Statements of Cash Flows – Nine-month periods ended September 30, 2017 and 2016 (unaudited)	.5
Notes to Consolidated Financial Statements (unaudited)	.6

SCOTTISH RE GROUP LIMITED CONSOLIDATED BALANCE SHEETS

(Expressed in Thousands of United States Dollars, except share data)

		eptember 30, 2017 (Unaudited)	I	December 31, 2016 (Audited)
Assets	¢	945 (49	¢	1 000 000
Fixed-maturity investments held as trading securities, at fair value	\$	845,648	\$	1,000,889
Fixed-maturity investments held as available-for-sale securities, at fair value (amortized cost: 2017 – \$649,595; 2016 – \$477,409)		658,663		478,128
Common stock investments held as available-for-sale securities, at fair value		038,003		4/0,120
(cost: 2017 - \$37,757)		37,896		_
Cash and cash equivalents		195,577		194,920
Other investments.		2,202		2,368
Funds withheld at interest		348,504		362,761
Total investments ¹		2,088,490		2,039,066
Accrued interest receivable ²		9,280		9,219
Amounts recoverable from reinsurers		587,987		652,536
Reinsurance balances receivable		154,656		194,882
Deferred acquisition costs		19,790		23,531
Other assets		795		1,290
Total assets	\$	2,860,998	\$	2,920,524
	Ψ	2,000,770	Ψ	2,920,921
Liabilities		1 000 550	¢	1 000 (50
Reserves for future policy benefits	\$	1,323,550	\$	1,392,659
Interest-sensitive contract liabilities		722,398		765,610
Collateral finance facility, net of debt issuance costs ³		448,405		447,978
Reinsurance balances payable		145,016		142,739
Accounts payable and other liabilities ⁴		117,480		101,858
Embedded derivative liabilities, at fair value		14,022		15,640
Long-term debt, at par value		86,500	¢	86,500
Total liabilities		2,857,371	\$	2,952,984
Shareholders' Equity (Deficit)				
Ordinary shares, par value \$0.01:		2 10 4		2 1 9 4
218,383,370 shares issued and outstanding		2,184		2,184
Non-cumulative perpetual preferred shares, par value \$0.01:				
3,246,776 shares issued and outstanding		81,169		81,169
Additional paid-in capital		1,772,547		1,772,547
Accumulated other comprehensive income (loss), net of taxes and deferred				
acquisition costs		8,374		628
Retained deficit		(1,860,647)		(1,888,988)
Total shareholders' equity (deficit)		3,627		(32,460)
Total liabilities and total shareholders' equity (deficit)	\$	2,860,998	\$	2,920,524
¹ Includes total investments of consolidated variable interest entity ("VIE")	\$	362,561	\$	278,216
² Includes accrued interest receivable of consolidated VIE		1,592		1,326
³ Reflects collateral finance facility, net of debt issuance costs, of consolidated VIE		448,385		448,056
		-		
⁴ Reflects accounts payable and other liabilities of consolidated VIE		90,153		76,602

SCOTTISH RE GROUP LIMITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(Expressed in Thousands of United States Dollars)

	Three-month period ended					Nine-month period ended				
	Sep	otember 30, 2017	Sej	ptember 30, 2016	Se	ptember 30, 2017	Se	ptember 30, 2016		
Revenues										
Premiums earned, net	\$	77,892	\$	74,494	\$	216,618	\$	234,465		
Investment income, net		15,313		15,711		45,788		49,800		
Net realized and unrealized gains (losses)		8,903		13,523		26,966		27,734		
Change in fair value of embedded derivative assets and liabilities		263		368		1,618		(1,249)		
Fees and other income		473		4,137		75,791		5,091		
Total revenues		102,844		108,233		366,781		315,841		
Benefits and expenses Claims, policy benefits, and changes in policyholder										
reserves, net Interest credited to interest-sensitive contract liabilities		81,667 4,981		93,364 5,408		265,072 15,037		281,549 16,319		
Other insurance expenses including amortization of		4,701		5,400		15,057		10,517		
deferred acquisition costs, net		7,842		15,443		25,805		32,994		
Operating expenses		6,841		4,377		17,405		12,397		
Collateral finance facilities expense		4,045		3,260		11,375		9,201		
Interest expense		1,305		1,106		3,746		3,192		
Total benefits and expenses		106,681		122,958		338,440		355,652		
Income (loss) before income taxes		(3,837)		(14,725)		28,341		(39,811)		
Income tax benefit (expense)		-		1,546		-		1,837		
Net income (loss)		(3,837)		(13,179)		28,341		(37,974)		
Other comprehensive income (loss), net of tax: Unrealized gains (losses) on available-for-sale investments, net of taxes and deferred acquisition										
costs		1,536		2,729		7,746		16,050		
Total other comprehensive income (loss), net of tax		1,536		2,729		7,746		16,050		
Total comprehensive income (loss)	\$	(2,301)	\$	(10,450)	\$	36,087	\$	(21,924)		

SCOTTISH RE GROUP LIMITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)

(Expressed in Thousands of United States Dollars)

	Nine-month period ended				
	September 30, 2017	September 30, 2016			
Share capital:					
Ordinary shares:					
Beginning of period	\$ 2,184	\$ 684			
Conversion of convertible cumulative participating preferred shares (par value)	-	1,500			
End of period	2,184	2,184			
Non-cumulative perpetual preferred shares:					
Beginning and end of period	81,169	81,169			
Additional paid-in capital:					
Beginning of period	1,772,547	1,218,190			
Conversion of convertible cumulative participating preferred shares (balancing figure)	-	554,357			
End of period	1,772,547	1,772,547			
Accumulated other comprehensive income (loss):					
Beginning of period.	628	(4,718)			
Other comprehensive income (loss), net of taxes and deferred acquisition costs	7,746	16,050			
End of period	8,374	11,332			
Retained deficit:					
Beginning of period	(1,888,988)	(1,680,837)			
Net income (loss)	28,341	(37,974)			
End of period	(1,860,647)	(1,718,811)			
Total shareholders' equity (deficit)	\$ 3,627	\$ 148,421			

SCOTTISH RE GROUP LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(Expressed in Thousands of United States Dollars)

	Nine-month period ended				
	Se	ptember 30, 2017	Se	ptember 30, 2016	
Operating activities					
Net income (loss)	\$	28,341	\$	(37,974)	
Adjustments to reconcile net income (loss) to net cash used in operating activities:					
Net realized and unrealized (gains) losses		(26,966)		(27,734)	
Changes in value of embedded derivative assets and liabilities		(1,618)		1,249	
Amortization (accretion) of fixed-maturity investments - available-for-sale		810		546	
Amortization of deferred acquisition costs		3,741		4,844	
Amortization of deferred finance facility costs		427		464	
Changes in assets and liabilities:					
Funds withheld at interest		14,257		20,649	
Accrued interest receivable		(61)		237	
Reinsurance balances receivable		40,226		(13,378)	
Other assets		(233)		2,527	
Reserves for future policy benefits, net of amounts recoverable from reinsurers		(4,560)		(3,131)	
Interest-sensitive contract liabilities		(14,043)		(14,086)	
Accounts payable and other liabilities, including deferred tax liabilities		15,622		10,653	
Reinsurance balances payable		2,277		6,435	
Net cash provided by (used in) operating activities		58,220		(48,699)	
Investing activities					
Purchase of fixed-maturity investments – available-for-sale		(211,876)		(138,457)	
Purchase of common stock investments – available-for-sale		(48,991)		-	
Proceeds from sales and maturities of fixed-maturity investments – trading		182,093		165,119	
Proceeds from sales and maturities of fixed-maturity investments – available-for-sale		38,878		9,331	
Proceeds from sales and maturities of common stock investments – available-for-sale		11,373		-	
Purchases of and proceeds from affiliated investments, net		-		(298)	
Purchase of and proceeds from other investments, net		166		274	
Net cash provided by (used in) investing activities		(28,357)		35,969	
Financing activities					
Withdrawals from interest-sensitive contract liabilities		(29,206)		(33,826)	
Net cash used in financing activities		(29,206)		(33,826)	
Net change in cash and cash equivalents		657		(46,556)	
Cash and cash equivalents, beginning of period		194,920		166,277	
Cash and cash equivalents, end of period	\$	195,577	\$	119,721	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

1. Organization, Business Strategy, Lines of Business, and Going Concern

Organization

Scottish Re Group Limited ("SRGL" and, together with SRGL's consolidated subsidiaries and, as a result of the application of FASB ASC 810-10 (as defined in Note 2, "Basis of Presentation" herein), its consolidated VIE*, as applicable, the "Company", "we", "our", and "us") is a holding company incorporated under the laws of the Cayman Islands, and with its principal executive office located in Bermuda. Through its operating subsidiaries, the Company is principally engaged in the reinsurance of life insurance, annuities, and annuity-type products. All of the equity voting power of SRGL, along with the right to designate a controlling number of members of SRGL's Board of Directors (the "Board"), is controlled directly or indirectly by MassMutual Capital Partners LLC, a member of the MassMutual Financial Group ("MassMutual Capital") and SRGL Acquisition, LDC, an affiliate of Cerberus Capital Management L.P. ("Cerberus" and, together with MassMutual Capital, the "Investors"). As of September 30, 2017, SRGL's consolidated subsidiaries (consisting of operating companies, holding companies, and financing companies) and its consolidated VIE (a collateral finance facility), by jurisdiction, were as follows:

Bermuda Scottish Re Life (Bermuda) Limited ("SRLB")

Cayman Islands Scottish Annuity & Life Insurance Company (Cayman) Ltd. ("SALIC")

<u>Ireland</u> Scottish Re (Dublin) dac ("SRD") Orkney Re II plc ("Orkney Re II")*

Luxembourg Scottish Financial (Luxembourg) S.á r.l. ("SFL")

<u>United States of America ("U.S." or "United States")</u> Scottish Holdings, Inc. ("SHI") Scottish Re (U.S.), Inc. ("SRUS")

* Orkney Re II is the consolidated VIE. References in the consolidated financial statements and accompanying notes to any discretionary acts of management or of any of the consolidated entities do not, unless explicitly stated otherwise, refer to any such acts by Orkney Re II.

Business Strategy

In 2008, our insurance operating companies ceased writing new business and notified existing clients that new reinsurance risks no longer would be accepted under existing reinsurance treaties, thereby placing the reinsurance business into run-off (the "Closed Block"). We continue to manage the Closed Block, performing key activities and actively managing the business under the terms of the related reinsurance treaties.

Lines of Business

As defined and described in our audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2016, we have written reinsurance business that is wholly or partially retained in one or more of our reinsurance subsidiaries and have classified the reinsurance as Traditional Solutions or as Financial Solutions.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

1. Organization, Business Strategy, Lines of Business, and Going Concern (continued)

Going Concern

These consolidated financial statements have been prepared using accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company's management assesses whether conditions and events raise substantial doubt that the Company will be able to continue as a going concern. Assessment of whether substantial doubt exists requires management to evaluate whether conditions and events, considered in the aggregate, indicate that it is probable that the Company will be unable to meet its obligations as they become due within one year of the issuance of the consolidated financial statements. Our ability to continue as a going concern is, therefore, dependent upon our ability to successfully meet our obligations, satisfy ongoing regulatory requirements and maintain adequate capital and liquidity.

As disclosed in the SRGL's audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2016, adverse mortality experience on the Traditional Solutions yearly renewable term ("YRT") business has had a substantial negative impact on the operating results. Absent a significant improvement in the performance of the Company's business during the remainder of 2017, the Company will incur additional capital strain, thereby further reducing available funds and eroding the Company's ability to pay the deferred interest on the Capital and Trust Preferred Securities (as defined herein) as such deferred interest payments become due during the first quarter of 2018. Accordingly, substantial doubt exists that the Company will be able to meet these deferred interest payments.

Management continues to monitor and evaluate alternatives to the current situation, however, there currently are no strategies that both are probable of effectively being implemented and that would supply funds in such amounts and at such times as would be necessary to mitigate the conditions and events described above.

These consolidated financial statements do not give effect to any adjustments to recorded amounts and their classification which would be necessary if a liquidation of the Company was imminent. Should this occur, we would be required to realize our assets and discharge our liabilities and commitments in other than the normal course of business and at amounts different from those reflected in the consolidated financial statements.

On May 17, 2017, SRGL commenced voluntary provisional winding up proceedings in Bermuda (where SRGL maintains its principal executive office) and filed for parallel winding up proceedings in the Cayman Islands (where SRGL is incorporated).

In connection with the Bermuda proceedings, on May 18, 2017, the Supreme Court of Bermuda granted an order appointing personnel from Finance & Risk Services Ltd. of Bermuda and Kalo (Cayman) Limited of the Cayman Islands as Joint Provisional Liquidators ("JPLs") of SRGL. As such, these JPLs are working with our Board and management to effectuate a restructuring plan for SRGL, which may involve the sale of SRGL's immediate subsidiary, SALIC. SRGL pro-actively filed these winding up petitions in an effort to facilitate the restructuring process and to maximize value to the Company's stakeholders. In addition, Keefe Bruyette & Woods, Inc., a Stifel Company, was retained to assist the Company in the process of identifying an acquirer for SALIC, which process is ongoing. However, there can be no assurances that this process will be successful, or even if successful, that it will not have a material adverse effect on SRGL's future financial statements and/or prospects.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

2. Basis of Presentation

Accounting Principles – Our consolidated interim financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles ("U.S. GAAP"). Accordingly, these consolidated interim financial statements do not include all of the information and notes required by U.S. GAAP for annual financial statements. These unaudited consolidated interim financial statements should be read in conjunction with SRGL's audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2016.

Consolidation – The consolidated interim financial statements include the assets, liabilities, and results of operations of SRGL, its subsidiaries, and the VIE for which we are the primary beneficiary, as defined in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Subtopic 810-10, Consolidation – Overall ("FASB ASC 810-10"). All significant intercompany transactions and balances have been eliminated in consolidation. We currently consolidate one non-recourse securitization, Orkney Re II, a special purpose VIE incorporated under the laws of Ireland. For further discussion on Orkney Re II, please refer to Note 5, "Collateral Finance Facility and Securitization Structure".

Estimates and Assumptions – The preparation of consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated interim financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions used by management, and such estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed herein.

Our most significant assumptions are for:

- investment valuations;
- accounting for embedded derivative instruments;
- assessment of risk transfer for structured insurance and reinsurance contracts;
- estimates of premiums;
- reserves for future policy benefits;
- retrocession arrangements and amounts recoverable from reinsurers;
- interest-sensitive contract liabilities; and
- current taxes, deferred taxes, and the determination of associated valuation allowances.

Where applicable, management periodically reviews and revises these estimates, as appropriate. Any adjustments made to these estimates are reflected in the period in which the estimates are revised.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

3. Investments

Trading Investments

The estimated fair values of our fixed-maturity investments held as trading securities as of September 30, 2017, and December 31, 2016, were as follows:

(U.S. dollars in thousands)		September 30, 2017	December 31, 2016			
U.S. Treasury securities and U.S. government agency obligations	\$	10,742	\$	17,682		
Corporate securities		256,843		293,161		
Municipal bonds		25,613		26,167		
Residential mortgage-backed securities		351,528		359,126		
Commercial mortgage-backed securities Asset-backed securities		100,252 100,670	_	112,129 192,624		
Total trading securities	\$	845,648	\$	1,000,889		

The contractual maturities of the fixed-maturity investments held as trading securities as of September 30, 2017, and December 31, 2016, were as follows (actual maturities may differ as a result of calls and prepayments):

(U.S. dollars in thousands)	E	stimated Fair Value September 30, 2017	Estimated Fair Value December 31, 2016				
Due in one year or less	\$	43,906	\$	34,631			
Due after one year through five years		168,207		196,056			
Due after five years through ten years		42,043		62,898			
Due after ten years		39,042	_	43,425			
		293,198		337,010			
Residential mortgage-backed securities		351,528		359,126			
Commercial mortgage-backed securities		100,252		112,129			
Asset-backed securities		100,670		192,624			
Total trading securities	\$	845,648	\$	1,000,889			

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

3. Investments (continued)

Available-for-Sale Investments

The cost or amortized cost and estimated fair value of all investments classified as available-for-sale as of September 30, 2017, and December 31, 2016, were as follows:

	September 30, 2017											
(U.S. dollars in thousands)												
	Cost or Amortized Cost		Gains	Te	emporary Losses	Tem	er Than iporary osses		estimated air Value			
U.S. Treasury securities and U.S.												
government agency obligations	\$ 20,700	\$	-	\$	(39)	\$	-	\$	20,661			
Corporate securities	337,071		8,341		(474)		-		344,938			
Municipal bonds	10,470		183		(48)		-		10,605			
Residential mortgage-backed	-								-			
securities	29,543		33		(56)		-		29,520			
Commercial mortgage-backed	,				× ,				,			
securities	31,458		419		(243)		-		31,634			
Asset-backed securities	220,353		972		(20)		-		221,305			
Total fixed-maturity securities	649,595		9,948		(880)		-		658,663			
Common stock	37,757		140		(1)		-		37,896			
Total available-for-sale securities.	\$ 687,352	\$	10,088	\$	(881)	\$	-	\$	696,559			

	December 31, 2016												
(U.S. dollars in thousands)													
		Cost or ortized Cost		Gains	Те	emporary Losses	Ten	er Than nporary Josses	Estimated Fair Value				
U.S. Treasury securities and U.S. government agency obligations Corporate securities	\$	23,701 285,453	\$	2,710	\$	(66) (1,706)	\$	-	\$	23,635 286,457			
Municipal bonds Residential mortgage-backed securities		4,477				(1,700) - (39)		-		4,448			
Commercial mortgage-backed securities		25,932		214		(476)		-		25,670			
Asset-backed securities Total fixed-maturity securities		137,846	<u> </u>	298 3,232		(226)		-		137,918 478,128			
Common stock Total available-for-sale securities	\$	477,409	\$	3,232	\$	(2,513)	\$	-	\$	478,128			

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

3. Investments (continued)

The estimated fair value and gross unrealized losses of all investments classified as available-for-sale, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position, as of September 30, 2017, and December 31, 2016, were as follows:

	September 30, 2017													
(U.S. dollars in thousands)]	Less than 1	onths	12 months or more					Total					
	Estima Fair V				Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses			
U.S. Treasury securities and U.S.	٠	10 (51	¢		¢	1 0 0 0	•		¢	20.661	¢	(20)		
government agency obligations.	\$	18,671	\$	(31)	\$	1,990	\$	(8)	\$	20,661	\$	(39)		
Corporate securities		31,858		(334)		5,426		(140)		37,284		(474)		
Municipal bonds		5,883		(48)		-		-		5,883		(48)		
Residential mortgage-backed														
securities		16,680		(28)		924		(28)		17,604		(56)		
Commercial mortgage-backed		-		~ /				~ /		<i>.</i>				
securities		6,274		(54)		5,889		(189)		12,163		(243)		
Asset-backed securities		13,903		(18)		8,266		(2)		22,169		(20)		
Total fixed-maturity securities		93,269		(513)		22,495		(367)		115,764		(880)		
Common stock		13,669		(1)		-		-		13,669		(1)		
Total available-for-sale securities	\$	106,938	\$	(514)	\$	22,495	\$	(367)	\$	129,433	\$	(881)		

	December 31, 2016													
(U.S. dollars in thousands)	Ι	Less than 1	onths	12	2 months o	or m	ore		Total					
	Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses			
U.S. Treasury securities and U.S. government agency obligations.	\$	23,635	\$	(66)	\$	-	\$	-	\$ 2	23,635	\$	(66)		
Corporate securities		98,857		(1,660)		1,450		(46)	10	0,307		(1,706)		
Municipal bonds		-		-		-		-		-		-		
Residential mortgage-backed securities Commercial mortgage-backed		979		(39)		-		-		979		(39)		
securities		10,101		(340)		1,705		(136)	1	1,806		(476)		
Asset-backed securities		28,033		(151)		22,035		(75)	4	50,068		(226)		
Total fixed-maturity securities		161,605		(2,256)		25,190		(257)	18	36,795		(2,513)		
Common stock		-		-		-		-		-		-		
Total available-for-sale securities	\$	161,605	\$	(2,256)	\$	25,190	\$	(257)	\$ 18	36,795	\$	(2,513)		

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

3. Investments (continued)

The total number of securities classified as available-for-sale that had unrealized losses as of September 30, 2017, and December 31, 2016, were 107 and 155, respectively. The Company's unrealized losses on its fixed maturity investments were the result of interest rate increases. Since the decline in estimated fair value is attributable to changes in interest rates and not credit quality, and the Company has the intent and ability to hold these maturities through a recovery of unrealized losses, or until maturity of the individual securities, the Company does not consider these investments other than temporarily impaired.

The contractual maturities of the fixed-maturity investments classified as available-for-sale securities as of September 30, 2017, and December 31, 2016, were as follows (actual maturities may differ as a result of calls and prepayments):

(U.S. dollars in thousands)		Cost or Amortized Cost September 30, 2017	<u>Estimated Fair Value</u> September30, 2017				
Due in one year or less	\$	9,340	\$	9,343			
Due after one year through five years	Ψ	129,122	Ψ	130,718			
Due after five years through ten years		208,540		214,136			
Due after ten years		21,239		22,007			
		368,241		376,204			
Residential mortgage-backed securities		29,543		29,520			
Commercial mortgage-backed securities		31,458		31,634			
Asset-backed securities		220,353		221,305			
Total fixed-maturity available-for-sale securities	\$	649,595	\$	658,663			

(U.S. dollars in thousands)		or Amortized Cost December 31, 2016	Estimated Fair Value December 31, 2016			
Due in one year or less	\$	5,156	\$	5,160		
Due after one year through five years		113,792		114,072		
Due after five years through ten years		181,782		182,338		
Due after ten years		8,424		8,522		
		309,154		310,092		
Residential mortgage-backed securities		4,477		4,448		
Commercial mortgage-backed securities		25,932		25,670		
Asset-backed securities		137,846		137,918		
Total fixed-maturity available-for-sale securities	\$	477,409	\$	478,128		

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

3. Investments (continued)

Assets on Deposit

We are required to maintain assets on deposit with various U.S. regulatory authorities, in accordance with the statutory regulations of the individual jurisdictions, to support our insurance and reinsurance operations. As a result of the various regulatory limitations on how these assets may be invested and their unavailability for general corporate purposes, these assets are considered "restricted". We also have established trust funds* in connection with certain transactions for the benefit of the transaction counterparties, which amounts also include assets attributable to the VIE that we consolidate, Orkney Re II. As a result of the restrictions imposed on the foregoing assets in accordance with the respective reinsurance treaties and other agreements to which they relate, these assets (including the assets within the collateral finance facility that are held for the contractual obligations of that structure) are not available for general corporate purposes and also are considered "restricted". (Please also refer to Note 5, "Collateral Finance Facility and Securitization Structure" for additional information.)

The estimated fair value of the components of the restricted assets as of September 30, 2017, and December 31, 2016, were as follows:

(U.S. dollars in thousands)		September 30, 2017	December 31, 2016			
Deposits with U.S. regulatory authorities	\$	4,580	\$	4,578		
Trust funds* attributable to VIE		521,578		437,957		
Trust funds*		775,188		717,065		
Total	\$	1,301,346	\$	1,159,600		

*"Trust funds" in the above table reflects the fair value of assets held by ceding companies under modified coinsurance arrangements and the fair value of assets we hold in segregated portfolios under coinsurance arrangements. The assets that comprise the "Trust funds" are included in fixed-maturity investments held as trading securities, fixed-maturity investments held as available-for-sale securities, common stock investments held as available-for-sale securities, cash and cash equivalents, and funds withheld at interest in the Consolidated Balance Sheets.

Net Investment Income

Net investment income on investments and other balances for the nine-month periods ended September 30, 2017 and 2016, was derived from the following sources:

(U.S. dollars in thousands)		-Month Period l September 30, 2017	Nine-Month Period Ended September 30, 2016			
Fixed-maturity investments, held as trading	\$	26,314	\$	32,093		
Fixed-maturity investments, held as available-for						
sale		12,638		9,705		
Common stock investments, held as available-for						
sale		129		-		
Funds withheld at interest		7,777		9,413		
Other investments		1,203		462		
Investment expenses	_	(2,273)		(1,873)		
Net investment income	\$	45,788	\$	49,800		

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

3. Investments (continued)

Realized and Unrealized Gains (Losses)

The components of realized and unrealized gains (losses) on investments and other balances for the nine-month periods ended September 30, 2017 and 2016, were as follows:

(U.S. dollars in thousands)		e-Month Period d September 30, 2017	Nine-Month Period Ended September 30, 2016		
Realized and unrealized gains (losses) Fixed-maturity investments					
Gross realized gains	\$	216	\$	1,500	
Gross realized losses		(10)		(10)	
Net unrealized gains (losses), trading securities		26,644		26,377	
		26,850		27,867	
Common Stock					
Gross realized gains	\$	139	\$	-	
		139		-	
Other					
Cerberus Affiliated Fund* - unrealized losses		-		(2,729)	
Cerberus Affiliated Fund* - realized gains Realized gains (losses) on modified coinsurance		-		3,433	
treaties		(37)		(853)	
Other		14		16	
	<u></u>	(23)	<u>_</u>	(133)	
Net realized and unrealized gains (losses)	\$	26,966	\$	27,734	
Change in net unrealized gains (losses) on available-for-sale investments					
Fixed-maturity investments		8,347		17,092	
Common stock investments		139		-	
Change in deferred income taxes		(179)		(254)	
Change in deferred acquisition costs		(561)		(788)	
Unrealized gains (losses) on available-for-sale investments, net of taxes and deferred acquisition costs	\$	7,746	\$	16,050	

* Defined in the "Affiliated Investments" section in this Note.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

3. Investments (continued)

Affiliated Investments

Affiliated investments represented investments accounted for under the equity method, in accordance with FASB ASC 323 Investments – Equity Method and Joint Ventures, for which the resulting equity method carrying value is deemed to approximate fair value. The investments accounted for under the equity method represented executed subscription documents, signed by SALIC on March 26, 2012, pursuant to which SALIC committed to make an investment of up to an aggregate \$30.0 million in an investment fund affiliated with and controlled, directly or indirectly, by Cerberus (the "Cerberus Affiliated Fund").

On December 1, 2016, SALIC entered into an agreement to sell to a third-party purchaser, in a privatelynegotiated transaction, its investment in the Cerberus Affiliated Fund for approximately \$35.9 million. The cost (capital commitment) of the Cerberus Affiliated Fund by SALIC at the time of the transaction was approximately \$28.9 million. The carrying value of the Cerberus Affiliated Fund at the time of the transaction was approximately \$41.8 million. In accordance with FASB ASC Topic 323, the Company recorded a \$5.9 million realized loss in the fourth quarter of 2016 on the Cerberus Affiliated Fund. The \$5.9 million realized loss on the Cerberus Affiliated Fund investment was included in the Consolidated Statements of Comprehensive Income for the year ended December 31, 2016, under the caption, "Net unrealized and unrealized gains (losses)".

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

4. Fair Value Measurements

FASB ASC 820 Fair Value Measurements and Disclosures ("FASB ASC 820") defines fair value, establishes a framework for measuring fair value based on an exit price definition, establishes a fair value hierarchy based on the quality of inputs used to measure fair value, and provides disclosure requirements for fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements), as described in Note 5, "Fair Value Measurements" in our audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2016, which, along with Note 3, "Investments" above, also includes additional disclosures regarding our fair value measurements.

Fair Value Measurements on a Recurring Basis

The following tables set forth our assets and liabilities that were measured at fair value on a recurring basis, as of the dates indicated:

	September 30, 2017								
(U.S. dollars in thousands)		Level 1		Level 2		Level 3		Total	
Investments – trading			· <u> </u>						
U.S. Treasury securities and U.S. government									
agency obligations	\$	-	\$	10,742	\$	-	\$	10,742	
Corporate securities		-		251,245		5,598		256,843	
Municipal bonds		-		25,613		-		25,613	
Residential mortgage-backed securities		-		84,030		267,498		351,528	
Commercial mortgage-backed securities		-		100,252		-		100,252	
Asset-backed securities		-		82,351		18,319		100,670	
Fixed-maturity investments, held as trading		-		554,233		291,415		845,648	
Investments – available-for-sale									
U.S. Treasury securities and U.S. government									
agency obligations	\$	-	\$	20,661	\$	-	\$	20,661	
Corporate securities		-		344,938		-		344,938	
Municipal bonds		-		10,605		-		10,605	
Residential mortgage-backed securities		-		29,520		-		29,520	
Commercial mortgage-backed securities		-		31,634		-		31,634	
Asset-backed securities		-		221,305		-		221,305	
Fixed-maturity investments, held as available-for-									
sale		-		658,663		-		658,663	
Common stock		-		37,896		-		37,896	
Total investments, held as available-for-sale		-		696,559		-		696,559	
Total assets at fair value	\$	-	\$	1,250,792	\$	291,415	\$	1,542,207	
Embedded derivative liabilities		_		-		(14,022)		(14,022)	
	\$		\$		\$	(14,022)	\$	(14,022)	
Total liabilities at fair value	φ	-	φ	-	φ	(14,022)	φ	(14,022)	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

4. Fair Value Measurements (continued)

	December 31, 2016									
(U.S. dollars in thousands)	Level 1		Level 2			Level 3		Total		
Investments – trading										
U.S. Treasury securities and U.S. government										
agency obligations	\$	-	\$	17,682	\$	-	\$	17,682		
Corporate securities		-		287,323		5,838		293,161		
Municipal bonds		-		26,167		-		26,167		
Residential mortgage-backed securities		-		99,982		259,144		359,126		
Commercial mortgage-backed securities		-		112,118		11		112,129		
Asset-backed securities		-		168,226		24,398		192,624		
Fixed-maturity investments, held as trading		-		711,498		289,391		1,000,889		
Investments – available-for-sale						,				
U.S. Treasury securities and U.S. government										
agency obligations	\$	-	\$	23,635	\$	-	\$	23,635		
Corporate securities		-		286,457		-		286,457		
Municipal bonds		-		-		-		-		
Residential mortgage-backed securities		-		4,448		-		4,448		
Commercial mortgage-backed securities		-		25,670		-		25,670		
Asset-backed securities		-		137,859		59		137,918		
Fixed-maturity investments, held as available-for-										
sale		-		478,069		59		478,128		
Total assets at fair value	\$	-	\$	1,189,567	\$	289,450	\$	1,479,017		
I otal assets at fair value	Ψ		Ŷ	1,109,007	Ŷ	207,100	<u> </u>	-,,011		
Embedded derivative liabilities		-		-		(15,640)		(15,640)		
Total liabilities at fair value	\$	-	\$	-	\$	(15,640)	\$	(15,640)		

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

4. Fair Value Measurements (continued)

The following tables present additional information about our assets and liabilities measured at fair value on a recurring basis for which we have utilized significant unobservable (Level 3) inputs to determine fair values:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3) for the nine-month period
ended September 30, 2017

(U.S. dollars in thousands)	rporate curities	nicipal onds	J	Residential mortgage- backed securities	ma b	nmercial ortgage- acked curities	ł	Asset- backed curities	-	Total assets at air value	Total liabilities at fair value
Beginning balance as of January 1, 2017 Total realized and unrealized gains (losses) included on trading securities in net	\$ 5,838	\$ -	\$	259,144	\$	11	\$	24,457	\$	289,450	\$ (15,640)
income Total unrealized gains (losses) included on available-for- sale securities in comprehensive net income	16	-		15,440		-		314		15,770	1,618
(loss)	-	-		-		-		11		11	-
Purchases	-	-		-		-		1,973		1,973	-
Settlements	(256)	-		(16,844)		(11)		(4,379)		(21,940)	-
Accretion (amortization)	-	-		9,758		-		56		9,814	-
Transfers into and/or (out of) Level 3, net	 -	 -		-		-		(4,113)		(4,113)	
Ending balance as of September 30, 2017	\$ 5,598	\$ -	\$	267,498	\$	-	\$	18,319	\$	291,415	\$ (14,022)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

4. Fair Value Measurements (continued)

Fair Value Measurements Using Significant Unobservable Inputs (Level 3) for the year ended
December 31, 2016

(U.S. dollars in thousands)	rporate curities	Μ	unicipal bonds	1	Residential mortgage- backed securities	ma b	nmercial ortgage- oacked curities	ł	Asset- backed curities	Total assets at air value	Total liabilities at fair value
Beginning balance as of January 1, 2016 Total realized and unrealized gains (losses) included on trading securities in net	\$ 6,996	\$	-	\$	267,849	\$	121	\$	26,110	\$ 301,076	\$ (16,871)
income Total unrealized gains (losses) included on available-for-sale securities in comprehensive net	(191)		-		(47)		2		15	(221)	1,231
income (loss)	-		-		(742)		-		(2)	(744)	-
Purchases Settlements Accretion (amortization) Transfers into and/or (out of) Level 3, net Ending balance as of December	 (1,067) 100		- - -		(23,088) 15,172		(113)		(1,352) 65 (379)	 (25,620) 15,338 (379)	- - -
31, 2016	\$ 5,838	\$		\$	259,144	\$	11	\$	24,457	\$ 289,450	\$ (15,640)

Changes in classifications impacting Level 3 financial instruments were reported in the above tables as transfers into (out of) the Level 3 category at the end of each quarterly period in which the transfers occurred. The portion of net unrealized gains for the three-month and nine-month periods ended September 30, 2017 related to Level 3 trading and available-for-sale securities still held at the reporting dates was \$6.9 million and \$16.3 million in net gains, respectively. The portion of net unrealized gains for the three-month and nine-month periods ended September 30, 2016 related to Level 3 trading securities still held at the reporting dates was \$6.1 million and \$3.7 million in net gains, respectively.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

4. Fair Value Measurements (continued)

The following tables summarizes the fair values, the valuation techniques, and the significant unobservable inputs of the Level 3 fair value measurements as of September 30, 2017, and December 31, 2016, for which we have been able to obtain quantitative information about the significant unobservable inputs used in those fair value measurements:

		Se	ptember 30, 2017		
Assets (U.S. dollars in millions)	Fa	ir Value	Valuation Technique	Significant Unobservable Inputs	Input Ranges
Corporate securities Mortgage and asset-backed	\$	1,504	Discounted Cash Flow Discounted Cash	Liquidity/duration adjustment* Liquidity/duration	0.9% - 1.3%
securities	\$	9,874	Flow	adjustment*	1.5% - 1.6%
		D	ecember 31, 2016		
Assets (U.S. dollars in millions)		ir Value	Valuation Technique	Significant Unobservable Inputs	Input Ranges
Corporate securities Mortgage and asset-backed	\$	1,761	Discounted Cash Flow Discounted Cash	Liquidity/duration adjustment* Liquidity/duration	1.1% - 1.7%

* The liquidity/duration adjustment input represents an estimated market participant composite interest spread that would be applied to the risk-free rate to discount the estimated projected cash flows for individual securities, and such liquidity/duration adjustment would reflect adjustments attributable to liquidity premiums, expected durations, credit structures, credit quality, etc., as applicable.

Flow

adjustment*

1.5% - 1.6%

10,228

\$

We have excluded from the tables above Level 3 fair value measurements obtained from independent, third-party pricing sources, including prices obtained from brokers, for which we do not develop the significant inputs used to measure the fair values and information regarding the significant inputs is not readily available to us from the independent, third-party pricing sources or brokers.

Fair Value Measurements on a Non-Recurring Basis

securities

As discussed in this Note, the fair values of financial assets and liabilities are estimated in accordance with the framework established under FASB ASC 820. The methodology for determining the fair value of financial instruments on a non-recurring basis, in addition to the fair value of financial instruments on a recurring basis and to those disclosed above in Note 3, "Investments", are described in Note 2, "Summary of Significant Accounting Policies - *Investments*", and Note 5, "Fair Value Measurements" in the Company's audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2016. The following tables sets forth the fair values of our financial instruments, as of the dates indicated:

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

4. Fair Value Measurements (continued)

	September 30, 2017										
(U.S. dollars in thousands)		Carrying Balance		Level 1	Level 2			Level 3			
			Estimated Fair Value								
Assets											
Cash and cash equivalents	\$	195,577	\$	195,577	\$	-	\$	-			
Other investments		2,202		-		-		2,202			
Funds withheld at interest		348,504		-		-		348,504			
Accrued interest receivable		9,280		-		9,280		-			
Liabilities											
Interest-sensitive contract liabilities Collateral finance facility, excluding debt issuance	\$	722,398	\$	-	\$	-	\$	721,844			
costs		450,000		-		-		215,857			
Embedded derivative liabilities, at fair value		14,022		-		-		14,022			
Long-term debt, at par value		86,500		-		60,398		-			

	December 31, 2016							
		Carrying						
(U.S. dollars in thousands)		Balance		Level 1	_	Level 2	_	Level 3
			Estimated Fair Value					
Assets								
Cash and cash equivalents	\$	194,920	\$	194,920	\$	-	\$	-
Other investments		2,368		-		-		2,368
Funds withheld at interest		362,761		-		-		362,761
Accrued interest receivable		9,219		-		9,219		-
Liabilities								
Interest-sensitive contract liabilities	\$	765,610	\$	-	\$	-	\$	765,069
Collateral finance facility, excluding debt issuance								
costs		450,000		-		-		171,601
Embedded derivative liabilities, at fair value		15,640		-		-		15,640
Long-term debt, at par value		86,500		-		51,633		-

5. Collateral Finance Facility and Securitization Structure

Orkney Re II

Historical information regarding the Orkney Re II collateral finance facility and securitization structure is discussed in Note 8, "Collateral Finance Facilities and Securitization Structures – Orkney Re II" in the Company's audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2016.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

5. Collateral Finance Facility and Securitization Structure (continued)

The following table reflects the significant balances included in the accompanying Consolidated Balance Sheets that were attributable to the Orkney Re II collateral finance facility and securitization structure providing collateral support to the Company:

	September 30, 2017		December 31, 2016	
(U.S. dollars in thousands)				
Assets				
Fixed-maturity investments held as available-				
for-sale securities, at fair value	\$	29,580	\$	8,072
Funds withheld at interest		380,933		376,623
Cash and cash equivalents		56,107		3,422
Embedded derivative assets		55,380		50,044
All other assets		12,858		5,211
Total assets	\$	534,858	\$	443,372
Liabilities				
Reserves for future policy benefits	\$	129,646	\$	130,106
Collateral finance facility		448,385		448,056
All other liabilities		90,153		78,030
Total liabilities	\$	668,184	\$	652,192

The assets listed in the foregoing table are subject to a variety of restrictions on their use, as set forth in and governed by the transaction documents for the Orkney Re II collateral finance facility and securitization structure. The total investments of the consolidated VIE disclosed in the accompanying Consolidated Balance Sheets include the deduction of the assets needed to satisfy future policy benefits, based on current projections ("economic reserves"). The following table provides a reconciliation of the aforementioned adjustments:

(U.S. dollars in thousands)	S	September 30, 2017		December 31, 2016	
Fixed-maturity investments held as available- for-sale securities, at fair value	\$	29,580	\$	8,072	
Funds withheld at interest		380,933		376,623	
Cash and cash equivalents		56,107		3,422	
Embedded derivative assets		55,380		50,044	
Total investments	\$	522,000	\$	438,161	
Less: Economic reserves		(159,439)		(159,945)	
Total investments in consolidated VIE	\$	362,561	\$	278,216	

The reinsurance liabilities of Orkney Re II have been eliminated from the Consolidated Balance Sheets.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

5. Collateral Finance Facility and Securitization Structure (continued)

Orkney Re II - Settlement of Litigation

On March 25, 2017, Orkney Re II agreed in principle to settle litigation brought by Assured, the guarantor of the Series A-1 Notes of Orkney Re II, in Assured's own right and in the right of Orkney Re II, against J.P. Morgan Investment Management, Inc. ("JPMIM"), the former investment manager of Orkney Re II, relating to the management of Orkney Re II's investment accounts, which were funded with the proceeds of the Orkney Re II Notes, as explained in Note 7, "Collateral Finance Facility and Securitization Structure" in the Company's audited consolidated financial statements and accompanying notes thereto for the year ended December 31, 2016. None of SRGL or its consolidated subsidiaries was a party to the settlement discussions.

Assured, suing in its own right and on behalf of Orkney Re II, commenced litigation against JPMIM in the Supreme Court of the State of New York on or about May 13, 2009. The legal proceedings had been ongoing since 2009, and up until the date of the settlement of March 25, 2017, there were no assurances over the outcome of the litigation.

Orkney Re II finalized the litigation settlement documentation and received \$74.4 million in cash on April 17, 2017, in return for releases of all claims by Orkney Re II and Assured in the litigation. None of SRGL or its consolidated subsidiaries was (i) a party to the litigation settlement; or (ii) was a direct beneficiary of any part of the settlement amount received by Orkney Re II.

Orkney Re II Event of Default, Acceleration and Foreclosure

Orkney Re II has been unable to make scheduled interest payments on the Series A-1 Notes and Series A-2 Notes on all scheduled quarterly interest payment dates since May 11, 2009. As of September 30, 2017, Assured Guaranty (UK) Ltd. ("Assured") has made guarantee payments in the cumulative amount of \$28.9 million on the Series A-1 Notes which are the subject of a financial guaranty policy issued by Assured in connection with the Orkney Re II transaction. Unlike the Series A-1 Notes, the Series A-2 Notes were not guaranteed under the Orkney Re II transaction and the amount of cumulative interest on the Series A-2 Notes was \$4.3 million as of September 30, 2017. We have accrued this amount of cumulative interest on the Series A-1 Notes and the Series A-2 Notes in Accounts Payable and Other Liabilities in the Consolidated Balance Sheets. Interest on the Series A-1 Notes on which Assured is making guarantee payments is payable quarterly at a rate equivalent to three-month LIBOR plus 0.425%.

As of September 30, 2017, the interest rate on the Series A-1 Notes was 1.73% (compared to 1.31% as of December 31, 2016). Interest on the Series A-2 Notes, which are not guaranteed as part of the Orkney Re II transaction, is payable quarterly at a rate equivalent to three-month LIBOR plus 0.730%. As of September 30, 2017, the interest rate on the Series A-2 Notes was 2.04% (compared to 1.62% as of December 31, 2016).

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

6. Debt Obligations and Other Funding Arrangements

Long-term debt, at par value (collectively, the "Capital and Trust Preferred Securities"), is individually defined and described in Note 9, "Debt Obligations and Other Funding Arrangements" in the notes accompanying the Company's audited consolidated financial statements for the year ended December 31, 2016. The pertinent details regarding long-term debt, at par value are shown in the following table:

(U.S. dollars in thousands)	Capital Securities Due 2032*	Preferred Trust Securities Due 2033*	Trust Preferred Securities Due 2033*	Trust Preferred Securities Due 2034*	Trust Preferred Securities Due December 2034*
Issuer of long-term debt	Capital Trust*	Capital Trust II*	GPIC Trust*	Capital Trust III*	SFL Trust I*
Long-term debt outstanding	\$17,500	\$nil**	\$nil***	\$19,000****	\$50,000
Maturity date	Dec 4, 2032	Oct 29, 2033	Sept 30, 2033	June 17, 2034	Dec 15, 2034
Redeemable (in whole or in part) after	Dec 4, 2007	Oct 29, 2008	Sept 30, 2008	June 17, 2009	Dec 15, 2009
Interest Payable	Quarterly	Quarterly	Quarterly	Quarterly	Quarterly
Interest rate: 3-month LIBOR +	4.00%	3.95%	3.90%	3.80%	3.50%
Interest rate as of September 30, 2017	5.33%	5.28%	5.23%	5.13%	4.83%
Interest rate as of December 31, 2016	5.00%	4.95%	4.90%	4.80%	4.50%
Maximum number of quarters for which interest may be deferred Number of quarters for which interest has	20	20	20	20	20
been deferred as of September 30, 2017	19	19	19	19	19

* Defined in the notes accompanying SRGL's audited consolidated financial statements for the year ended December 31, 2016. **SRGL owns all \$20.0 million of the Preferred Trust Securities Due 2033 securities.

***SRGL owns all \$10.0 million of the Trust Preferred Securities Due 2033 securities.

****SRGL owns \$13.0 million of the Trust Preferred Securities Due 2034 securities.

Deferral of Interest Payments on the Capital and Trust Preferred Securities

We began deferring interest payments as of January 29, 2013 on the Capital and Trust Preferred Securities as permitted by the terms of the indentures governing the securities. As of September 30, 2017, we had accrued and deferred payments of \$29.0 million in interest on the Capital and Trust Preferred Securities. Of these deferred payments, \$9.9 million are attributable to SRGL, leaving a net amount of accrued deferred interest of \$19.1 million on the Capital and Trust Securities due to external parties. SHI, SFL, and SALIC generally are restricted in their ability to make certain dividend payments and payments in respect of obligations ranking junior or *pari passu* to the Capital and Trust Preferred Securities in any period where interest payment obligations on these securities are not current.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

7. Mezzanine Equity – Convertible Cumulative Participating Preferred Shares

On May 7, 2007, we completed the equity investment transaction by the Investors, announced by us on November 27, 2006 (the "2007 New Capital Transaction"). Pursuant to the 2007 New Capital Transaction, the Investors invested an aggregate \$600.0 million in the Company in exchange for 1,000,000, in the aggregate, newly-issued Convertible Cumulative Participating Preferred Shares (the "CCPP Shares"). Aggregate net proceeds of \$555.9 million were received after payment of \$44.1 million in closing costs. Each CCPP Share had a par value of \$0.01 per share with an initial stated value and liquidation preference of \$600 per share, as adjusted for the accretion of dividends or the payment of dividends or distributions as described further below.

The CCPP Shares were convertible at the option of the holder, at any time, into an aggregate of 150,000,000 ordinary shares (the "Ordinary Shares") of SRGL. We accounted for the 2007 issuance of the CCPP Shares to the Investors, in accordance with FASB ASC Subtopic 470-20, Debt – Debt with Conversion and Other Options ("FASB ASC 470-20"), which incorporates EITF D-98: "Classification and Measurement of Redeemable Securities". We were not required at any time to redeem the CCPP Shares for cash, except in the event of a liquidation or upon the occurrence of a change-in-control event.

On the ninth anniversary of issue, May 7, 2016, and in accordance with the CCPP Certificate of Designations, the CCPP Shares automatically converted into an aggregate of 150,000,000 Ordinary Shares of the Company.

We accounted for the conversion of the CCPP Shares in accordance with FASB ASC 470-20. As a result, and in accordance with the CCPP Certificate of Designations, the CCPP Shares were converted into an aggregate of 150,000,000 Ordinary Shares, with each Ordinary Share having a par value of \$0.01, representing an additional \$1.5 million in the Ordinary Shares amount in the Company's Consolidated Balance Sheets. The remaining balance of the CCPP Shares amount of approximately \$554.4 million that was previously classified under Mezzanine Equity in the Consolidated Balance Sheets, and was over and above the Ordinary Share conversion amount of \$1.5 million as described earlier, was reclassified to Additional Paid-in Capital ("APIC").

The conversion of the CCPP Shares had no material impact on the results of operations of the Company and only impacted the Consolidated Balance Sheets.

The table below provides an illustration of the changes to the Company's Consolidated Balance Sheets as follows:

	May 6, 2016	Adjustment	May 7, 2016	
(U.S. dollars in thousands) Total Mezzanine Equity		()		
Total Mezzanine Equity	<u>\$ 555,857</u>	(555,857)	<u>\$</u>	
Total Mezzanine Equity	\$ 555,857	\$ (555,857)	\$ -	
Equity Share Capital APIC Share Capital & APIC	\$ 684 <u>1,218,190</u> \$ 1,218,874	\$ 1,500 554,357 \$ 555,857	\$ 2,184 <u>1,772,547</u> \$ 1,774,731	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

8. Shareholders' Equity

Ordinary Shares

We are authorized to issue 590,000,000 Ordinary Shares with a par value of \$0.01 per share.

As of September 30, 2017, and December 31, 2016, we had 218,383,370 Ordinary Shares issued and outstanding.

Perpetual Preferred Shares

We are authorized to issue 50,000,000 preferred shares with a par value of \$0.01 per share.

In 2005, we issued 5,000,000 Non-Cumulative Perpetual Preferred Shares (the "Perpetual Preferred Shares"). Gross proceeds were \$125 million, and related expenses were \$4.6 million. As of September 30, 2016, and December 31, 2015, we have repurchased and cancelled 1,753,224 Perpetual Preferred Shares. As of September 30, 2017, and December 31, 2016, we had 3,246,776 Perpetual Preferred Shares issued and outstanding.

The dividend rate on the Perpetual Preferred Shares may be at a fixed rate determined through remarketing of the Perpetual Preferred Shares for specific periods of varying length not less than six months or may be at a floating rate reset quarterly based on a predefined set of interest rate benchmarks. The quarterly floating rates for September 30, 2017 and 2016 were 6.31% and 5.98%, respectively. During any dividend period, unless the full dividends for the current dividend period on all outstanding Perpetual Preferred Shares have been declared or paid, no dividend may be paid or declared on the Ordinary Shares and no Ordinary Shares or other junior shares may be purchased, redeemed, or otherwise acquired for consideration by SRGL. Please refer below to "*Dividends on Perpetual Preferred Shares*" in the Note below for additional information.

Dividends on Ordinary Shares

The Investors, as the holders of the Ordinary Shares, are entitled to receive dividends and are allowed one vote per share subject to certain restrictions in our Memorandum and Articles of Association.

All future payments of dividends are at the discretion of our Board and will depend on such factors as the Board may deem relevant. Notwithstanding the foregoing, if dividends on the Perpetual Preferred Shares have not been declared and paid (or declared and a sum sufficient for the payment thereof set aside) for a dividend period, we are precluded from paying or declaring any dividend on the Ordinary Shares during such period.

Dividends on Perpetual Preferred Shares

In accordance with the relevant financial tests under the terms of the Perpetual Preferred Shares, our Board was precluded from declaring and paying a dividend in connection with the January 15, April 15, and July 15, 2016 dividend payment dates.

In accordance with the relevant financial tests under the terms of the Perpetual Preferred Shares, our Board was permitted to declare and pay dividends for the October 15, 2016, the January 15, 2017, and the April 15, 2017 dividend payment dates. Our Board resolved, in its discretion, not to declare and pay a dividend on the Perpetual Preferred Shares on the October 15, 2016, the January 15, 2017, and the April 15, 2017 dividend shares.

There can be no assurances when or whether, as a result of the application of the financial tests contained in the terms of the Perpetual Preferred Shares, our Board will be permitted to make subsequent dividend payments on the Perpetual Preferred Shares or, if permitted, when or whether our Board will choose in its discretion to make any such dividend payments on the Perpetual Preferred Shares.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

8. Shareholders' Equity (continued)

For further discussion on the non-declaration of the Perpetual Preferred Shares dividends, please refer to Note 11, "Subsequent Events – *Non-declaration of Dividend on Perpetual Preferred Shares*".

Perpetual Preferred Shares – Right to Appoint Directors

Pursuant to the terms of, and subject to the procedures set forth in, the Certificate of Designations related to the Perpetual Preferred Shares (the "PPS Certificate of Designations"), the holders of the Perpetual Preferred Shares are entitled to elect two directors to our Board in the event dividends on the Perpetual Preferred Shares have not been declared and paid for six or more dividend periods, whether or not consecutive (a "Nonpayment"). Failure to declare and pay dividends on the July 15, 2009 dividend payment date marked the sixth dividend period for which dividends had not been declared and paid (i.e., a Nonpayment). That year, pursuant to the PPS Certificate of Designations, the Company provided notice to the holders of the Perpetual Preferred Shares of the Nonpayment and the right to elect two directors.

If and when dividends for at least four dividend periods, whether or not consecutive, following a Nonpayment have been paid in full, this right will cease.

On September 18, 2015, the Company received correspondence from Mr. Paul Davis, a purported beneficial holder of the Perpetual Preferred Shares, seeking to initiate the process for the election of directors by holders of the Perpetual Preferred Shares. Subsequently, we provided to our Transfer Agent and Registrar on October 9, 2015, a notice to holders of the Perpetual Preferred Shares addressing certain procedures related to the election of directors, including a request that holders of the Perpetual Preferred Shares nominate candidates for election to the Board and provide the names and contact information for such nominees. On November 5, 2015, the Company received a letter from Cede & Co., the nominee of The Depository Trust Company ("DTC"), a holder of record of Perpetual Preferred Shares, which included a written consent from Mr. Davis, purporting to designate Mr. Davis as a director of SRGL. The written consent did not satisfy the requirements of the PPS Certificate of Designations and instead operated as a nomination of Mr. Davis for potential election by holders of the Perpetual Preferred Shares. The Company notified Mr. Davis of such circumstances and reiterated a request for certain information regarding Mr. Davis as set out in the Company's October 9, 2015 notice. The Company provided Mr. Davis a Director Nominee Questionnaire seeking additional information required for holding an election pursuant to the PPS Certificate of Designations. Upon receipt of a completed Director Nominee Questionnaire, the Company would plan to proceed to convene a special meeting of the holders of Perpetual Preferred Shares to vote on the election of Mr. Davis as a Director of SRGL. At no time during 2015 or 2016 did Mr. Davis respond to our request for such required information, and no other nominations were received in response to the Company's October 9, 2015 request.

On June 29, 2017, the Company received correspondence on behalf of Mr. Davis, that included a completed Director Nominee Questionnaire (as provided to Mr. Davis in late 2015), and renewed his request to be appointed to the SRGL Board.

On July 10, 2017, the Company advised Mr. Davis that it was promptly evaluating the items noted in his June 29, 2017 correspondence. On July 11, 2017, the Company received additional correspondence on behalf of Mr. Davis, again demanding Mr. Davis be appointed to the SRGL Board.

By correspondence dated July 14, 2017, the Company responded to Mr. Davis informing him that his 2017 correspondence failed to satisfy the terms of the PPS Certificate of Designations for the election of Perpetual Preferred Shares directors. In addition, the Company set out its intention to establish a process to allow for the election of Mr. Davis to the SRGL Board in compliance with the PPS Certificate of Designations. The Company informed Mr. Davis that the first step in this process would require him to submit to the Company, in writing, a certification of his current beneficial ownership of Perpetual Preferred Shares. In addition, and assuming Mr. Davis' holdings remained through the Depositary Trust Company and consist of at least 20% of the outstanding Perpetual Preferred Shares, Cede & Co., as a record holder of Perpetual Preferred Shares, would need to request a special meeting of Perpetual Preferred Shares

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

8. Shareholders' Equity (continued)

holders for the election of two additional directors to the Board in accordance with the PPS Certificate of Designations and nominate Mr. Davis for one of the Perpetual Preferred Share director positions.

Mr. Davis subsequently advised that he is the current beneficial owner of 20% of the Perpetual Preferred Shares through DTC. As a result, we instructed our Transfer Agent and Registrar, on September 21, 2017, to notify the holders of the outstanding Perpetual Preferred Shares that SRGL was accepting nominations for the Perpetual Preferred Share director positions, and further that a special meeting would be held on October 30, 2017, to nominate Mr. Davis for one of the Perpetual Preferred Share director positions, and to elect two additional directors to the SRGL Board in accordance with the PPS Certificate of Designations.

For further discussion regarding the potential exercise of the Perpetual Preferred Shares right to appoint Directors, please refer to Note 11, "Subsequent Events – *Perpetual Preferred Shares – Right to Appoint Directors*".

9. Income Taxes

There was no income tax expense or benefit for the nine-month period ended September 30, 2017. The income tax expense for the nine-month period ended September 30, 2016 was \$1.8 million. Any net incomes from the operations of our Cayman Island entities are not subject to income tax. The operations of our U.S., Bermuda, and Irish entities did not generate a current tax expense, due to the operating performance and the availability of tax losses from prior tax years. The utilization of tax losses results in a reduction in deferred tax assets and a corresponding reduction in the valuation allowance established against those deferred tax assets.

As of September 30, 2017, we had total unrecognized tax benefits (excluding interest and penalties) of \$1.5 million, the recognition of which is not expected to create a tax benefit at the effective tax rate for the applicable period. The total unrecognized tax benefits figure (excluding interest and penalties) and the resulting tax benefit recognition figure were unchanged from December 31, 2016.

As of September 30, 2016, we had total unrecognized tax benefits (excluding interest and penalties) of \$1.5 million, the recognition of which is not expected to create a tax benefit at the effective tax rate for the applicable period. The total unrecognized tax benefits figure (excluding interest and penalties) and the resulting tax benefit recognition figure were unchanged from December 31, 2015.

Our deferred tax assets are principally supported by the reversal of deferred tax liabilities. We currently establish a valuation allowance against deferred tax assets when it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. We have maintained a full valuation allowance against any remaining deferred tax asset associated with our operations in the U.S. and Ireland, given our inability to rely on future taxable income projections and the scheduling of our current deferred tax liabilities.

As of September 30, 2017, and December 31, 2016, the projections of GAAP life insurance reserves no longer provide for deferred tax liabilities that reverse after the expiration of net operating loss carryforwards in applicable jurisdictions. Therefore, a scheduled deferred tax liability, in excess of the established valuation allowance, has not been recorded as of September 30, 2017, and December 31, 2016.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

9. Income Taxes (continued)

We file our tax returns as prescribed by the tax laws of the jurisdictions in which we operate. As of September 30, 2017, we remained subject to examination in the following major tax jurisdictions for the returns filed for the years indicated below:

Major Tax Jurisdictions	Open Years			
U.S.				
Life Group	2014 through 2016			
Non-Life Group	2014 through 2016			
Ireland	2013 through 2016			

Our U.S. subsidiaries are subject to U.S. federal, state, and local corporate income taxes and other taxes applicable to U.S. corporations. Upon distribution of current or accumulated earnings and profits in the form of dividends or otherwise from our U.S. subsidiaries to us, we would be subject to U.S. withholding taxes at a 30% rate.

Net operating losses are being carried forward from closed years and could be examined by the applicable tax authorities if utilized in an open tax year in the future. Additionally, to the extent that a net operating loss is carried back to an otherwise closed year, that earlier year could be subject to examination as long as the loss year remains open.

10. Commitments and Contingencies

Ballantyne Re plc

Ballantyne Re plc ("Ballantyne Re"), which previously was a consolidated VIE of the Company, is a special purpose reinsurance vehicle incorporated under the laws of Ireland. In May 2006, Ballantyne Re issued, in a private offering, \$1.74 billion of debt to third party investors, \$178.0 million of Class C Notes to SALIC, \$181.2 million in preference shares to SALIC, and \$500,000 in Class D Notes to SRGL.

We have no remaining direct loss exposure related to Ballantyne Re since our interests in the Ballantyne Re Class D Notes and Preferred Shares are valued at \$0. The Class C Notes were fully written-off in 2008 under the contractual terms of the Ballantyne Re indenture.

SRUS remains liable for the accuracy and performance of certain representations, warranties, covenants, and other obligations that relate to periods before the assignment and novation to Security Life of Denver Insurance Company of the reinsurance agreement with Ballantyne Re. In addition, SRGL and SRUS remain responsible for certain ongoing covenants and indemnities made for the benefit of Ballantyne Re and the financial guarantors of certain of the notes issued by Ballantyne Re.

Indemnification of Our Directors, Officers, Employees, and Agents

We indemnify our directors, officers, employees, and agents against any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, by reason of the fact that they are our director, officer, employee, or agent, as provided in our Articles of Association. Since this indemnity generally is not subject to limitation with respect to duration or amount, we do not believe that it is possible to determine the maximum potential amount due under this indemnity in the future.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

10. Commitments and Contingencies (continued)

Davis v. Scottish Re Group Limited, et al.

SRGL and SRUS (together, "Scottish Re") learned that a lawsuit was filed on or about November 20, 2013, in New York state court against Scottish Re, SRGL's shareholders and certain of their affiliates, and various former and current directors of Scottish Re (collectively, the "Defendant Parties"). The plaintiff, identified in the court documents as a holder of Perpetual Preferred Shares and a former holder of Ordinary Shares (please refer to Note 8, "Shareholders' Equity" for information regarding the Perpetual Preferred Shares and the Ordinary Shares), alleges, among other things, claims against the Defendant Parties for breach of contract, breach of fiduciary duty, tortious interference, and derivative claims centered largely around the following events:

- the 2011 unwind of a formerly consolidated collateral finance facility and the associated acquisition by Cerberus affiliates of debt related to the collateral finance facility;
- the completion in 2011 of a cash-out merger between SRGL and affiliates of the Investors;
- the cancellation by SRGL of Perpetual Preferred Shares acquired pursuant to cash tender offers made by SRGL in 2010 and 2012; and
- a purported distribution policy affecting the Perpetual Preferred Shares.

On February 21, 2014, Motions to Dismiss were filed with the court on behalf of the Defendant Parties pursuant to a briefing schedule previously agreed with the court and the plaintiff. Pursuant to that schedule, the plaintiff submitted on May 7, 2014 its opposition to the Motions to Dismiss. The Defendant Parties submitted replies in further support of their Motions to Dismiss on June 23, 2014. Oral arguments on the Motions to Dismiss were heard by the court on September 29, 2014.

Following oral arguments on the Motions to Dismiss on September 29, 2014, on October 7, 2014, the presiding judge issued a decision dismissing all claims against the Defendant Parties, with the exception of two breach of contract claims against SRGL. The judge directed that the plaintiff and SRGL engage in jurisdictional discovery limited to these two claims, after which the court would decide whether these claims should also be dismissed on jurisdictional grounds.

The plaintiff filed on October 28, 2014 his opening appellate brief challenging the court's October 7, 2014 decision. Following this, Scottish Re and the other Defendant Parties filed opposition briefs, and the plaintiff thereafter filed his reply brief. Oral arguments on the appellate brief were heard by the Appellate Division of the New York Supreme Court on June 9, 2015.

Jurisdictional discovery commenced on the two breach of contract claims concluded on October 26, 2015. Thereafter, the Company filed with the court its renewed Motion to Dismiss in respect of the two remaining claims. Pursuant to the schedule agreed with the court, the plaintiff's brief opposing the Motion to Dismiss was filed with the court on November 25, 2015 and the Company's reply was filed on December 16, 2015. A hearing on the Company's renewed Motion to Dismiss was held with the trial court on January 26, 2016.

On March 10, 2016, the appellate court issued a decision on the plaintiff's appeal argued before it on June 9, 2015, relating to the trial court's previous dismissal of eight of the ten claims originally brought by the plaintiff in this case. The appellate court's majority decision (representing three of the five justices) affirmed the trial court's dismissal of all but two of the claims on appeal against all defendants. With respect to the remaining claims, the appellate court remanded the matter to the trial court to allow the plaintiff to re-plead two breach of fiduciary duty claims against the three Directors of SRGL who remain in the case (the "Director Defendants"). The two dissenting justices would have affirmed the dismissal of all claims on appeal.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

10. Commitments and Contingencies (continued)

On April 25, 2016, the plaintiff filed a motion with appellate court, seeking permission to appeal the dismissal of three derivative breach of fiduciary duty claims to the New York Court of Appeals. On May 12, 2016, the Director Defendants who remain in the case and SRGL's shareholders and certain of their affiliates filed an opposition brief to plaintiff's motion. On May 18, 2016, the plaintiff filed a reply brief in further support of his motion.

Notwithstanding the appellate court's March 10, 2016 decision remanding the matter to the trial court to allow the plaintiff to replead only two breach of fiduciary duty claims against the remaining Director Defendants, on May 3, 2016, the plaintiff filed an amended complaint with the trial court in which the plaintiff repleaded eight of the original ten claims, removing two of the original claims and adding a new claim against certain of the Defendant Parties. On June 7, 2016, the Director Defendants filed a Motion to Dismiss the repleaded breach of fiduciary duty claims. On July 14, 2016, the plaintiff filed his response to the Director Defendants' Motion to Dismiss the repleaded breach of fiduciary duty claims. The reply brief of the Director Defendants was filed on August 5, 2016. Oral arguments for the Director Defendant's Motion to Dismiss the repleaded breach of fiduciary duty claims were held on November 7, 2016. On July 19, 2017, the trial court issued a Decision and Order dismissing seven of the eight claims asserted in the plaintiff's amended complaint. The only claims currently pending in the trial court are the breach of fiduciary claim against the three Director Defendants and a breach of contract claim against Scottish Re. The parties each have filed an appeal of the Decision and Order with the New York Appellate Division. The plaintiff filed his brief on September 8, 2017.

On July 7, 2016, the appellate court granted plaintiff's motion for leave to appeal the dismissal of the three derivative breach of fiduciary duty claims to the New York Court of Appeals. On September 27, 2016, the plaintiff filed his opening brief in the New York Court of Appeals. The response brief by the Director Defendants who remain in the case and SRGL's shareholders and certain of their affiliates was filed on November 17, 2016. The plaintiff's reply brief was filed on December 5, 2016. Oral argument was scheduled for October 10, 2017.

On July 11, 2016, the trial court issued a ruling that dismissed one of the two breach of contract claims asserted against Scottish Re. The plaintiff did not file an interlocutory appeal from the dismissal prior to the deadline for doing so. On August 22, 2016, the plaintiff served discovery requests with respect to the one remaining breach of contract claim against Scottish Re and the breach of fiduciary claim against the three Director Defendants.

Scottish Re has certain obligations to indemnify those Defendant Parties who are current or former directors for the reasonable cost of their defense of the Davis lawsuit.

We believe the plaintiff's allegations to be without merit and are vigorously defending our interest in the action. Accordingly, it is not possible to estimate any loss in respect of the plaintiff's claims.

For further discussion regarding the Davis v. Scottish Re Group Limited, et al. litigation, please refer to Note 11, "Subsequent Events – *Commitments and Contingencies – Davis v. Scottish Re Group Limited, et al.*".

Other Contingencies

On January 20, 2016, SRUS initiated an arbitration proceeding against a third-party ceding company related to a dispute regarding the applicable premium tables and other related claims in respect of certain business ceded to SRUS from the third-party ceding company. The arbitration hearing was held the last week of June 2017. The arbitrators issued a Decision and Award that was received on July 26, 2017. SRUS prevailed on the two main issues that were pending before the arbitrators. There is no resulting material impact to the Company's financial statements as a result of the Decision and Award.

On April 22, 2016, SRUS initiated an arbitration proceeding against a third-party ceding company seeking among other things, the enforcement of certain premium calculations under various YRT reinsurance agreements between the third-party ceding company and SRUS, as well as rescission of some YRT reinsurance agreements based

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

10. Commitments and Contingencies (continued)

upon misrepresentations and mismanagement by the third-party ceding company. On September 30, 2016, SRUS sent a notice to the third-party ceding company that SRUS was terminating the reinsurance for non-payment of premiums pursuant to the terms of the YRT reinsurance agreements. On October 20, 2016, SRUS received a counter-demand to the arbitration demand from the third-party ceding company alleging certain issues relating to premium calculation and certain claims ceded to SRUS. The parties have tentatively agreed to a final hearing date during the week of February 5, 2018. Discovery is underway.

On October 6, 2016, SRUS received an arbitration demand from a third-party ceding company related to a YRT reinsurance agreement. The arbitration demand alleges certain issues relating to premium calculation and certain claims ceded to the Company. On October 21, 2016, SRUS responded to the arbitration demand, denying each of the allegations. SRUS also served a counter-demand on the third-party ceding company seeking, among other things, rescission of the YRT reinsurance agreement based upon misrepresentations and mismanagement by the third-party ceding company, and the enforcement of certain premium calculations under the YRT reinsurance agreement. The parties have selected an arbitration panel. An organizational meeting was held on May 9, 2017, at which time the parties agreed to a final hearing date beginning on March 12, 2018. Discovery is underway.

On June 1, 2017, SRUS received an arbitration demand from a third-party ceding company related to certain YRT reinsurance agreements. The arbitration demand alleges certain issues relating to premium calculation. SRUS has retained outside counsel.

11. Subsequent Events

The subsequent events disclosed in these notes to the consolidated financial statements have been evaluated by Company management up to and including the filing of these consolidated financial statements on October 27, 2017.

Non-declaration of Dividends on Perpetual Preferred Shares

On October 27, 2017, our Board resolved, in its discretion, not to declare and pay a dividend on the Perpetual Preferred Shares on the October 15, 2017 dividend payment date.

Perpetual Preferred Shares - Right to Appoint Directors

The Company did not receive any additional nominations for the Perpetual Preferred Share director positions by the October 6, 2017 deadline set forth in the September 21, 2017 notification to holders of the outstanding Perpetual Preferred Shares. Accordingly, Mr. Davis is the sole nomination and is expected to be elected as a director to the SRGL Board, with immediate effect, at the special meeting of the holders of the Perpetual Preferred Shares on October 30, 2017, in accordance with the PPS Certificate of Designations.

Commitments and Contingencies

Davis v. Scottish Re Group Limited, et al.

Oral arguments before the New York Court of Appeals were held on October 10, 2017 in respect of the plaintiff's appeal of the dismissal of the three derivative breach of fiduciary duty claims. No ruling has been issued as of the date of these financial statements.

The Director Defendants filed their brief with the New York Appellate Division on October 16, 2017 in respect of their appeal of the July 19, 2017 Decision and Order of the trial court.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

September 30, 2017

11. Subsequent Events (continued)

At the request of the trial court, the parties will submit to the trial court a proposed discovery schedule on November 2, 2017 with respect to the single breach of contract claim against SRGL and the pending breach of fiduciary duty claim against the Director Defendants.